Published in Cancer on May 19, 2014
The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature. J Surg Oncol (2015) 2.06
Sarcopenia is more than simply documenting low skeletal muscle mass. Cancer (2014) 1.40
Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience. Cent European J Urol (2015) 0.97
Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools. Urol Oncol (2015) 0.92
Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging (2015) 0.91
Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle (2016) 0.84
Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. World J Urol (2015) 0.82
Skeletal muscle mass is associated with severe dysphagia in cancer patients. J Cachexia Sarcopenia Muscle (2015) 0.81
Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle (2016) 0.80
Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. World J Urol (2016) 0.78
Evaluation and Management of the Geriatric Urologic Oncology Patient. Curr Geriatr Rep (2015) 0.78
Association of Weight Change after Colorectal Cancer Diagnosis and Outcomes in the Kaiser Permanente Northern California Population. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. Int J Clin Oncol (2016) 0.77
Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol (2015) 0.77
Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting. J Urol (2014) 0.76
90-Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study. World J Urol (2016) 0.76
Total Psoas Area Predicts Complications following Radical Cystectomy. Adv Urol (2015) 0.76
Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. BMC Cancer (2017) 0.75
Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. J Cachexia Sarcopenia Muscle (2015) 0.75
Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Bladder Cancer (2017) 0.75
Reply to sarcopenia is more than simply documenting low skeletal muscle mass. Cancer (2014) 0.75
Progress in Fully Automated Abdominal CT Interpretation. AJR Am J Roentgenol (2016) 0.75
Prognostic significance of sarcopenia in upper tract urothelial carcinoma patients treated with radical nephroureterectomy. Cancer Med (2016) 0.75
Preoperative frailty predicts postoperative complications and mortality in urology patients. World J Urol (2016) 0.75
A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. BMC Urol (2017) 0.75
Assessing the effects of modality of surgery on postoperative weight loss in patients undergoing partial nephrectomy. World J Urol (2016) 0.75
Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients. Sci Rep (2017) 0.75
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Meckel diverticulum: the Mayo Clinic experience with 1476 patients (1950-2002). Ann Surg (2005) 4.72
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol (2010) 2.38
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol (2007) 2.36
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol (2010) 2.05
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int (2004) 2.00
The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol (2013) 1.99
Nomenclature of natural orifice translumenal endoscopic surgery (NOTES) and laparoendoscopic single-site surgery (LESS) procedures in urology. J Endourol (2008) 1.97
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem (2008) 1.87
Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc (2013) 1.87
Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urologic Association surgeons. BJU Int (2012) 1.87
Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol (2003) 1.82
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol (2002) 1.82
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol (2003) 1.81
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol (2005) 1.80
Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer (2011) 1.80
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int (2011) 1.78
Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer (2012) 1.78
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology (2010) 1.77
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol (2010) 1.76
Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol (2012) 1.75
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol (2008) 1.73
Outcomes following partial nephrectomy by tumor size. J Urol (2008) 1.72
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer (2005) 1.71
Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy. J Urol (2011) 1.69
Long-term complications of conduit urinary diversion. J Urol (2010) 1.66
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol (2009) 1.63
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res (2005) 1.61
Perivascular epithelioid cell tumor (PEComa) of the urinary bladder: report of 3 cases and review of the literature. Am J Surg Pathol (2009) 1.60
Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer (2009) 1.60
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res (2007) 1.59
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int (2013) 1.59
Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol (2004) 1.58
AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer (2005) 1.58
The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol (2012) 1.58
T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res (2008) 1.58
Contemporary trends in nephrectomy for renal cell carcinoma in the United States: results from a population based cohort. J Urol (2011) 1.57
Renal carcinoid tumor: a clinicopathologic study of 21 cases. Am J Surg Pathol (2007) 1.57
Percutaneous renal cryoablation: local control at mean 26 months of followup. J Urol (2010) 1.55
Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol (2005) 1.55
Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol (2007) 1.53
Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol (2012) 1.53